Positive CHMP Opinions Received for Novel Bispecific Antibodies TALVEY® (talquetamab) and TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/positive-CHMP-opinions-talvey-tecvayli)